Paclitaxel (PTX) is one of the most potent intravenous chemotherapeutic agents to date, yet an oral formulation has been problematic because of its low solubility and permeability. Using the recently discovered solubilizing properties of rubusoside (RUB), we investigated the unique PTX-RUB formulation. PTX was solubilized by RUB in water to levels of 1.6-6.3 mg/ml at 10-40% weight/volume. These nanomicellar PTX-RUB complexes were dried to a powder, which was subsequently reconstituted in physiologic solutions. After 2.5 h, 85-99% of PTX-RUB remained soluble in gastric fluid, whereas 79-96% remained soluble in intestinal fluid. The solubilization of PTX was mechanized by the formation of water-soluble spherical nanomicelles between PTX and RUB, with an average diameter of 6.6 nm. Compared with Taxol, PTX-RUB nanoparticles were nearly four times more permeable in Caco-2 cell monocultures. In a side-by-side comparison with dimethyl sulfoxide-solubilized PTX, PTX-RUB maintained the same level of cytotoxicity against three human cancer cell lines with IC 50 values ranging from 4 to 20 nmol/l. In addition, tubule formation and migration of human umbilical vein endothelial cells were inhibited at levels as low as 5 nmol/l. These chemical and biological properties demonstrated by the PTX-RUB nanoparticles may improve oral bioavailability and enable further pharmacokinetic, toxicologic, and efficacy investigations. Anti-Cancer Drugs 26:167-179
Introduction
Paclitaxel (PTX) is by far the most potent, naturally occurring, anticancer chemotherapeutic ( Fig. 1 ), which acts through tubulin binding, thus disrupting DNA duplication [1] . Half maximal inhibitory concentrations (IC 50 ) against a wide variety of human cancer cells were reported to be in the lower nanomolar range (1-10 nmol/l) for PTX. Other commonly used chemotherapeutic agents such as camptothecin achieved the same efficacy at higher nanomolar ranges (10-100 nmol/l) [2] , or in the micromolar range, as seen with etoposide [3] , temozolomide [4] , curcumin [5, 6] , and resveratrol [7] . However, the pharmacological advantage of PTX is hampered by its low solubility and permeability. PTX is a nonionizable, lipophilic, and nonpolar molecule, which adversely affects its solubility. In addition, PTX is a P-glycoprotein (P-gp) substrate, whereby some cell types can easily pump PTX back into the extracellular space. In the biopharmaceutical classification system, PTX is categorized as a biopharmaceutical classification system intravenous drug, the most difficult category for oral drug delivery.
The solubility constraints of PTX have been addressed in Taxol by the cosolvency approach or in Abraxane by conjugation with a water-soluble albumin carrier. These two intravenous PTX drugs are currently prescribed to treat ovarian, breast, non-small-cell lung, small-cell lung, and head and neck cancers. PTX solubilized in Cremophor EL or dehydrated ethanol as in Taxol has been a frontline chemotherapeutic agent since 1992; however, hypersensitivity reactions resulting from the use of Cremophor EL limit the treatment intensity necessary to achieve optimal clinical efficacy [8] . Solubilizing PTX by conjugation with albumin (Abraxane) is an improvement and eliminates most of the hypersensitivity side effects. Intravenous drugs, as opposed to oral formulations, are not encumbered by gastrointestinal (GI) barriers to reach the circulation such as changing pH, mucous layers, tight junctions, and P-gp pumps.
Converting intravenous drugs to oral medications would offer significant advantages [9] . Intravenous infusions generally require cancer patients to visit an outpatient facility or a physician's office for therapy. These infusions are costly, often induce nausea, and require lengthy office visits that may not be available locally. Developing an oral PTX formulation has proven to be difficult. Not only is PTX difficult to solubilize, it is poorly absorbed through the intestinal epithelium. First-pass metabolism may further reduce PTX's chance to enter the systemic circulation structurally intact [10] . PTX (Abraxane) is not suitable for oral administration because albumin, as a protein carrier, degrades in the GI tract. Cremophor ELsolubilized PTX (Taxol) is suitable for oral delivery, but PTX cannot be protected from the P-gp efflux pump and may be entrapped in Cremophor [11, 12] . Finding an effective way to solubilize PTX and enhance its oral absorption using excipients that impose minimal or no toxicity remains an elusive goal for an oral PTX formulation.
In our research on natural products, the solubilizing property of steviol glycosides, such as rubusoside (RUB; Fig. 2 ) was discovered [13] . Several lipophilic chemotherapeutic compounds have been solubilized with RUB including PTX, curcumin, and etoposide [2, 3, 6] . Furthermore, RUB has demonstrated the ability to inhibit P-gp [14] . This discovery, and an initial solubilization success, prompted the present study examining the feasibility of using RUB as a solubilizer and a P-gp inhibitor to support an oral PTX medication. Furthermore, we examined the mechanism of solubility enhancement, the stability profiles in physiologic fluids, and maintenance of indicated biological properties of the PTX-RUB nanoparticles.
Materials and methods

Chemicals
Acetonitrile and water were of high-performance liquid chromatography grade (HPLC; Mallinckrodt Baker Inc., Phillipsburg, New Jersey, USA). PBS (1 × ) was purchased from MP Biomedicals LLC (Solon, Ohio, USA). Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were purchased from RICCA Chemical Co. (Arlington, Texas, USA). PTX with a purity of 99.5% was purchased from LC Laboratories (Woburn, Massachusetts, USA). RUB was isolated from Rubus suavissimus S. Lee (Rosaceae) in our own laboratory and was structurally elucidated by nuclear magnetic resonance and mass spectrometry analyses [15] . The purity of RUB was determined to be greater than 98% by HPLC-UV. Dimethyl sulfoxide (DMSO) was of analytical grade (Fisher Scientific Inc., Fair Lawn, New Jersey, USA). The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] solution and phenazine methosulfate were purchased from Promega Co. (Madison, Wisconsin, USA).
High-performance liquid chromatography protocols
An HPLC system (Waters, Milford, Massachusetts, USA) was used for the analyses. The system included a pump, an online degasser, a column heater compartment, an autosampler, and a photodiode array detector. Empower 1 workstation software (Waters) was used for equipment control, as well as for data acquisition and processing. All of the analyses were carried out on a reverse-phase Symmetry C18 HPLC column (150 × 4.6 mm internal diameter, 5 μm; Waters) at 30°C. For PTX detection, elution was performed with an isocratic gradient of acetonitrile and water (52 : 48). For RUB detection, elution was performed with an isocratic gradient of acetonitrile and water (33 : 67). The flow rate of the mobile phase was 1.0 ml/min and the injection volume of the sample was 2 μl. The photodiode array detector was in a wavelength range of 200-600 nm and the selected detection wavelength was 230 nm for PTX and 215 nm for RUB. The concentrations of PTX were determined using a serial of PTX standard solutions in methanol between 100 μg/ml and 2.0 mg/ml. The concentrations of RUB were determined using a serial of RUB standard solutions in water between 10 and 100 mg/ml. All samples were centrifuged at 14 000 rpm for 10 min before injection.
Solubilization of paclitaxel by rubusoside
A solvent evaporation method was used to prepare the complex of PTX and RUB. Appropriate amounts of RUB and PTX were weighed at a ratio of 50 : 1 weight/weight (w/w). Thereafter, 10 ml of absolute ethanol was added to the mixture, vortexed slightly, and heated in a water bath as needed to form a clear ethanol solution containing 2 mg/ml PTX and 100 mg/ml RUB. The ethanol solution was passed through nylon 0.45 µm nylon filters (Whatman, Maidstone, Kent, UK) to eliminate larger particles present in the solution. The ethanol solution was allowed to stand at room temperature (22°C) for 60 min and was then completely evaporated to a powder under reduced pressure, at 50°C, and agitation in a RAPIDVAP system (Labconco, Kansas City, Missouri, USA). The powder of the PTX and RUB (PTX-RUB) complex was reconstituted with HPLC-grade water and centrifuged at 20 800 rcf (14 000 rpm) for 10 min. The supernatant water solution was injected and analyzed for PTX and RUB.
Characterization of the complex formed between paclitaxel and rubusoside Determination of surface morphology
The surface morphology of the complex structure formed between PTX and RUB was studied using freezefracture transmission electron microscopy (TEM). To do this, the PTX-RUB powder was first reconstituted in water so that the RUB concentration was 10% w/v. Freeze-fracture samples were prepared by first depositing a drop of the 10% w/v RUB-solubilized PTX water solution onto a copper planchette (BAL-TEC, Los Angeles, California, USA). The sample was frozen by rapid immersion into a liquid Freon (SHUR/Freeze Cryogen Spray; Triangle Biomedical Sciences, Durham, North Carolina, USA) bath, after which it was plunged into liquid nitrogen. The vitrified sample was transferred to the sample stage, which was submerged in liquid nitrogen. After transferring the sample stage into the freeze-etching chamber of the Balzers BAF-400 apparatus, the samples were fractured at a temperature of − 170°C
. Once the fractured sample was allowed to etch for about 1 min, Pt-C was deposited at a 45°angle with respect to the sample surface, followed by deposition of C at a 90°angle for reinforcement. The resulting replicas were washed twice in distilled water to remove the actual sample. The replicas were collected on 400 mesh Formvar-coated grids (Electron Microscopy Sciences, Hatfield, Pennsylvania, USA) and allowed to dry overnight. TEM observations were made with a JEOL JEM-100CX transmission electron microscope operated at 80 kV (JEOL Inc., Peabody, Massachusetts, USA).
Particle size measurement
Particle size measurements were made using a custombuilt dynamic light scattering (DLS) apparatus equipped with a Coherent Innova 90 argon (400-800 nm) laser (Laser Innovations, Santa Paula, California, USA), set to 568.2 nm. A Pacific Precision Instruments (Irvine, California, USA) wide-range photometer/preamplifier/discriminator drives an ALV pulse shaper, which feeds an ALV-5000 digital autocorrelator (Pacific Precision Instruments). Ten percent w/v RUB-solubilized PTX water solution was transferred into clean cells through 0.22 µm Millipore Durapore membrane filters. The temperature was controlled at 25.0 0.01°C by a circulating water bath. For each sample, five repetitive runs, each of 180-s duration, were conducted. Each sample was run five times at 90°scattering angle, with a duration of 180 s each. The averaged correlation functions were analyzed with one-exponential and third-order cumulant algorithm to determine the apparent hydrodynamic diameter, D h .
Reconstitution of paclitaxel-rubusoside powder in physiologic solutions
The PTX-RUB powder was reconstituted in distilled and deionized water (control), PBS solution, SGF, and SIF. All reconstituted solutions were analyzed for pH using a pH meter (Accumet Basic; Fisher Scientific, Waltham, Massachusetts, USA) and for the concentrations of PTX and RUB by HPLC.
Stability of the paclitaxel-rubusoside nanoparticles in physiologic solutions over time and in response to dilutions
The PTX-RUB powder was reconstituted to stock solutions in three replicates in water (control), PBS solution, SGF, or SIF. Each reconstituted stock solution contained 10% w/v RUB and was then diluted by 1.3-fold, two-fold, four-fold, or 10-fold with the same solvent. All solutions were incubated at 37°C. The concentrations of PTX in the diluted solutions were measured at 0.25, 2.5, 5.0, 7.5, 10, 12.5, and 24 h by HPLC. Results are expressed as mean SD.
Permeability assessment Caco-2 cell culture
Caco-2 cells (ATCC CRL-2102; ATCC, Manassas, Virginia, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and allowed to grow to 4 × 10 5 cells/ ml before passaging. The passaged Caco-2 cells (< 10 passages) were grown in a 75 cm 3 flask to a density of ∼ 250 000 cells/cm 2 . These cells were then trypsinized from maximally (90%) confluent Caco-2 cultures and resuspended in DMEM. The cell suspension was transferred to a test tube and allowed to sediment to remove the debris and large cell aggregates (if any). The supernatant was then transferred to a new test tube, an aliquot of which was taken for cell count. After cell counting, the supernatant was spun down to remove the supernatant solution. These cells (at a concentration of 2.0 × 10 5 cells/ ml) were then resuspended in DMEM supplemented with antibiotics including penicillin and streptomycin (Invitrogen Corporation, Carlsbad, California, USA).
Caco-2 cell monolayer culture
The assay was conducted in a 24-well plate with an insert membrane (Millipore 24-well membrane inserts with a surface area of 0.31 cm 2 , membrane diameter of 6.5 mm, and pore size of 3.0 µmol/l) in each well. Before seeding these cells onto the insert membrane, the cells were mixed to minimize sedimentation or agglomeration. The insert membranes were prewetted with 0.1 ml of medium (for at least 2 min) before seeding the cells. To seed, 0.4 ml of the resuspended cell solution was dispensed onto each insert membrane. The seeding density was 8 × 10 4 cells/insert. The basolateral chamber was filled with 1.0 ml of DMEM supplemented with the triple antibiotic pack consisting of penicillin, streptomycin, and amphotericin B (MP Biomedicals, Solon, Ohio, USA) at 100 IU/ml, and 100 and 0.25 µg/ml, respectively. After seeding, the plate containing these inserts was incubated at 37°C and 5% CO 2 in a humid atmosphere for 6-12 h to allow attachment of cells onto the insert membrane. After the attachment period, the apical medium containing the unattached cells was carefully aspirated and replaced with 0.4 ml of DMEM supplemented with the antibiotics. To grow the cells in a monolayer, medium from both the apical and basolateral sides were replaced with fresh medium every other day for up to 21 days. Cell monolayer formation and integrity were measured using an Epithelial Voltohmmeter (EVOM 2 ; World Precision Instruments, Sarasota, Florida, USA) for transepithelial electrical resistance (TEER). When the values of TEER reached within the range of 250-650 Ω/cm 2 , permeability experiments were started.
Permeability assay
The culture medium was first changed 12-24 h before the experiment was started. PTX was first solubilized in either Cremophor EL/ethanol (used in Taxol) or water for PTX-RUB; thereafter, it was diluted with a transport buffer with pH in the range of 6.5-7.2. The final PTX concentration was 60 µg/ml in the transport buffer solution containing either 5.2 mg/ml Cremophor EL and 5.0 µl/ml ethanol (PTX-Taxol) or 3.0 mg/ml RUB (PTX-RUB). To determine the cytotoxicity of RUB as a solubilizer, drug-free RUB was assayed in separate Caco-2 cells at a concentration range of 0.6 mmol/l (0.35 mg/ml) to 77.9 mmol/l (50 mg/ml) following the procedure described below. This was done to determine a nontoxic concentration of RUB to Caco-2 cells, at which they still formed a monolayer for the permeability assay. Ranitidine and warfarin, each at 10 µmol/l, were used as low-permeability and high-permeability controls, respectively. The TEER values of each well were taken before adding the test compounds and at 2 h. For each insert, a 300 µl aliquot of test compound dissolved in transport buffer was first added to the insert (donor solution). Then 1000 µl of transport buffer was added to the well (receiver solution). The plate was then incubated at 37°C in a humidified atmosphere for 120 min. At completion, 300 µl of the donor solution and 1000 µl of the receiver solution were taken and stored at − 18°C for subsequent HPLC analyses. The apical to basolateral apparent permeability (P app ) was calculated on the basis of the following equation:
; where dQ/dt = flux from donor to receiver, VA = volume of receptor chamber (cm 3 ), A = area of the membrane insert (0.31 cm 2 ), T = assay time (s).
Cytotoxicity of paclitaxel-rubusoside nanoparticles Solubilization and sample preparation
To evaluate the cytotoxicity of RUB-solubilized PTX, a side-by-side comparison with DMSO-solubilized PTX was performed using a standard MTS cell viability assay. Two PTX stock solutions were prepared by either solubilizing the free PTX in absolute DMSO (PTX-DMSO) at a concentration of 23.4 µmol/l or reconstituting the PTX-RUB powder in water to a concentration of 234.2 µmol/l. The PTX-DMSO stock solution was diluted with culture medium by 10-fold, whereas the PTX-RUB stock solution by 100-fold, such that both assay solutions contained 2.34 µmol/l PTX. These assay solutions were further serially diluted to a range of 0.91-117 nM using culture medium with either 1% v/v DMSO (for PTX-DMSO) or 0.01% w/v RUB (for PTX-RUB).
Cell culture
The human prostate carcinoma (DU145), breast carcinoma (MDA-MB-231), and human colon adenocarcinoma (HT-29) cell lines were obtained from the American Type Culture Collection (ATCC) and maintained at 37°C in a humidified atmosphere with 5% CO 2 . Cells were cultured in DMEM supplemented with 10% FBS, N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), penicillin-streptomycin, sodium pyruvate, L-glutamine, and nonessential amino acids. All cell culture materials were purchased from Invitrogen Corporation.
In-vitro cell viability assays: cell viability was tested using the MTS assay. HT-29, DU145, or MDA-MB-231 cells were added to 96-well plates at a concentration of 1 × 10 4 cells/well, respectively, and allowed to adhere overnight. The cells were then treated with the PTX-RUB nanoparticle solutions prepared above, with 0.91-117 nM PTX, in triplicate wells and incubated at 37°C for 96 h. On day 4, a 20 μl aliquot of MTS solution premixed with phenazine methosulfate was added directly to each well and the plate was incubated at 37°C for another 1-2 h. Absorbance was measured at a wavelength of 490 nm using a Bio-Rad Microplate Reader (Hercules, California, USA). Percent viability was calculated as cell viability relative to the vehicle-treated control (100%). The IC 50 values were the average of at least two independent experiments.
Angiogenesis of human umbilical vascular endothelial cells Tube formation
The human umbilical vein endothelial cells (HUVECs) were purchased from ATCC (#CRL-1730). HUVECs were grown in M199 media containing 20% FBS, 30 μg/ ml endothelial cell growth supplements, 4 mmol/l L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 . They were treated with PBS containing 1% DMSO or RUB as the vehicle controls and various concentrations of PTX in either DMSO or RUB system for 24 h. Tube formation was recorded under a microscope connected to a digital camera.
Migration
Migration of HUVECs was assessed by scraping a zone free from HUVECs. After 6 h of incubation with vehicle controls or various concentrations of PTX in DMSO or RUB system, digital images were taken under a microscope. Clear zones indicated complete inhibition of HUVEC migration, whereas invasion of neighboring HUVECs indicated partial or no inhibition.
Statistical analysis
All data were analyzed using the paired Student's t-test or one-way analysis of variance followed by Tukey's posthoc test (SAS, Cary, North Carolina, USA). Data were expressed as mean SE unless otherwise specified. Significance of all tests was set at a P-value of up to 0.05.
Results
Solubilization of paclitaxel by rubusoside
Using the organic solvent evaporation method, a powder was obtained that contained 2% w/w PTX and 98% w/w RUB. This powder was instantly and completely reconstituted to water solutions with various percentages of RUB. Corresponding to 1, 2.5, 5, 7.0, 9.1, 20, and 40% w/ v RUB, PTX was solubilized to 0.08, 0.27, 0.66, 1.10, 1.57, 3.54, and 6.26 mg/ml (Table 1) , respectively. pH values of the reconstituted PTX-RUB water solutions increased slightly from 5.7 to 6.2 as the concentrations of both PTX and RUB increased. The volume of the water solutions increased by 0 (no change), 1, 4, 7, 9, 11, and 15% after the addition of 1, 2.5, 5, 7.5, 10, 20, and 40% w/v PTX-RUB powder, respectively. There were no unknown peaks detected in the chromatogram (Fig. 3) , an indication of the structural stability of both the drug and the solubilizer during the solubilization process. By reconstituting the powder to a 40% RUB water solution, a PTX concentrate was made. This concentrate contained 6.3 mg/ml PTX and was clear and transparent (Fig. 4) .
Reconstitutability of the paclitaxel-rubusoside nanoparticles in physiologic solutions
The PTX-RUB nanoparticulate powder was reconstituted in water, PBS saline, SGF, or SIF. In the reconstituted solutions, PTX and RUB concentrations were consistent with the values expected ( Table 2) based on the knowledge of PTX content in the powder. The pH of the reconstituted water solutions depended on the type of media. pH values were 6.20, 7.21, 1.12, and 5.75, respectively, for water, PBS saline, SGF, and SIF.
Size and shape of the paclitaxel-rubusoside nanoparticles in a water solution On the basis of the linear behavior of the semilogarithmic plot shown in Fig. 5a , the PTX-RUB complexes were (Fig. 5b) .
Although conclusive evidence about the size and dispersity of the solution was obtained from the semilogarithmic plot of the autocorrelation function, further distribution analyses reaffirmed these findings (data not shown). Figure 6 shows the freeze-fracture TEM images of a reconstituted PTX-RUB nanoparticle water solution, in which the numerous spherical dark spots are believed to be the complex particles formed between PTX and RUB in the nanometer range, in agreement with the results of DLS.
Stability of the paclitaxel-rubusoside nanoparticles in physiologic solutions over time and in response to dilutions Stock solutions were prepared by reconstituting the PTX-RUB powder in water, PBS saline, SGF, and SIF, respectively. These reconstituted transparent stock solutions contained ∼ 10% w/v RUB and 1.6 mg/ml of PTX. When the respective stock solutions were diluted by factors of 1.3, 2, 4, and 10 with a respective medium, RUB concentrations were, respectively, 7.5, 5, 2.5, and 1% w/v with no observable precipitation at the outset. Subsequently, the PTX concentrations declined over time in all four dilutions, as well as in the stock physiologic solutions (Fig. 7) . PTX-RUB complexes showed the least precipitation in water (Fig. 7a) and the most in PBS saline (Fig. 7b) , whereas results were in-between for SGF (Fig. 7c) and SIF (Fig. 7d) . In the stock solutions (10% RUB), which were prepared by direct reconstitution of the PTX-RUB powder, PTX precipitated from 1.2 to 6.8% at 2.5 h and from 9.4 to 30.3% by 24 h. At lower RUB concentrations (1-7.5%), which were prepared by dilution of the stock solutions, PTX precipitated at a higher rate, where as much as 64.7% precipitated out by 24 h in the PBS/2.5% RUB solution.
In contrast to PTX, RUB concentrations remained unchanged in all physiologic solutions over a period of 24 h (Fig. 8 ).
Permeability across Caco-2 cell monolayer PTX-RUB nanoparticles were more permeable through the monolayer than the PTX-Taxol system. PTX-RUB showed a permeability coefficient of 3.83, ∼ 3.5 times the permeability coefficient of PTX-Taxol (Table 3) . PTX in the PTX-RUB nanoparticles was fully solubilized by a single natural compound, RUB, at 4.7 mmol/l (3 mg/ml) in water without any organic solvent, whereas PTX in the Taxol formulation was fully solubilized by the combination of Cremophor EL (5.2 mg/ml) and ethanol (5.0 µl/ml). At 4.7 mmol/l or lower, RUB did not affect the cell viability of Caco-2 monolayers (Fig. 9) . RUB alone started to reduce cell viability at a concentration of 4.7 mmol/l and completely inhibited cell growth at 19.5 mmol/l, with an IC 50 value of 10.4 mmol/l (6.7 mg/ml). (Fig. 10) . RUB alone (vehicle) had no effect on the viability of any cell line. No differences in cancer cell inhibition were observed between PTX-DMSO and PTX-RUB solutions (Table 4) .
Antiangiogenic properties of the paclitaxel-rubusoside nanoparticles
HUVECs under control conditions developed healthy, normal tubes. The 1% DMSO or RUB vehicle had no effect on tube formation or cell migration. The addition of solubilized PTX to the cell culture, however, resulted in visible effects on the formation of tubules and cell migration. PTX, starting at the 5 nmol/l concentration and regardless of the DMSO-solubilized or RUBsolubilized system, disrupted the completion of tube formation (Fig. 11a ) and prevented cell migration (Fig. 11b) . These inhibitory effects became more profound as the concentrations of PTX increased to 25 and 50 nmol/l.
Discussion
Various strategies have been used to solubilize PTX but here we report solubilization of PTX with the natural product RUB. Solubility levels of 1.6-6.3 mg/ml of PTX in physiologic solutions were achieved using 100-400 mg/ml RUB. RUB is more efficient at solubilization of PTX than the Cremophor EL/absolute ethanol combination. RUB at 400 mg/ml can solubilize PTX to 6 mg/ml, the same level achieved by the use of 527 mg/ ml Cremophor EL and 497 µl/ml absolute ethanol, as used in Taxol. The ability to form a powder from the RUB/PTX solution and its subsequent reconstitutability expand the range of dosage forms possible compared with those seen with nonaqueous liquid formats. Solubilization of PTX has been extensively studied using conventional techniques, initially to replace the toxic Cremophor EL. Of late, emphasis has shifted to developing oral PTX formulations. Three major strategies for oral delivery of PTX have been adopted and are summarized in Table 5 . Recently polymeric nanoparticles of various types have become a major strategy for pharmaceutical delivery, whereby PTX was loaded into lipophilic nanoparticle cores. Various types of nanoparticle cores have been constructed to host the lipophilic PTX, such as poly(D,L-lactide-co-glycolide) and poly(D, L-lactide) [25] , D-α-tocopheryl polyethylene glycol 1000 FF-TEM image of PTX-RUB complexes, seen as spherical particles (dark spots in the background of slide material). FF-TEM, freeze-fracture transmission electron microscopy; PTX, paclitaxel; RUB, rubusoside.
Paclitaxel natural nanoparticles
succinate [26, 27] , β-casein micelles [28] , gelatin [29] , and lipid nanocapsules [9, 30] . These constructed nanoparticles are not water soluble and must be coated and solubilized with surfactants such as polyethylene glycol, polysorbate 80 (Tween 80), and Solutol for oral delivery. Some polymeric nanoparticle cores are constructed with built-in solubilizing factors through conjugation of the core with a solubilizing agent (e.g. polyethylene glycol). In these cases, PTX-loaded nanoparticle cores require no additional solubilizing agent [19] [20] [21] [22] [23] 31] . Cosolvency is another strategy used to create water-soluble formulations for oral delivery of PTX, as seen with Taxol. Complexation, such as the use of cyclodextrins, is the third strategy used to solubilize PTX for oral delivery [32] [33] [34] .
In comparison with conventional nanocore surfactant approaches, RUB serves as a nanocore and a solubilizer for the PTX-RUB nanoparticles. In the current study, we demonstrated the feasibility of RUB as a PTX solubilizer. PTX was molecularly dispersed into RUB at a ratio of 1 : 50 by weight. We achieved a solubility level of 6.3 mg/ ml of PTX by reconstituting the powder into a clear and transparent water solution as a PTX concentrate (Fig. 4) . At 6.3 mg/ml, the solubility of PTX is enhanced by nearly 18 000-fold compared with that seen in water (350 ng/ml) and by 120 times the minimum requirement of 52 μg/ml for pharmaceutical drugs on the basis of a 1 mg/kg clinical dose with average permeability [35] .
The mechanism of solubilization of PTX by RUB appears to be the formation of water soluble micellar nanoparticles between PTX and RUB, similar to the mechanism observed for the micellar nanoparticles formed between curcumin and RUB, as well as etoposide and RUB [3, 6] . Along with a similar solubilization Stability of PTX in physiological solutions and its response to dilution by a factor of 1.3, 2, 4, and 10 over 24 h following sample preparation at 37°C. Each data point represents the mean of three replicates SD. PTX, paclitaxel.
mechanism, the particle size among the three compounds is also similar (PTX, 7 nm; curcumin, 8 nm; etoposide, 6 nm). It is noticeable that the PTX-RUB nanoparticles observed under TEM (Fig. 6) were not of one size, as that found by DLS (Fig. 5) . It is possible that during sample preparations for TEM imaging, nanoparticles may have overlaid and formed aggregates. Compared with existing formulations developed for PTX, the PTX-RUB nanoparticles were the smallest in size while in solution (Table 5) . Particle size has been implicated as an important factor affecting cellular entry and transport. In a study on the chemotherapeutic agent etoposide, a particle size of 105 nm was shown to sustain plasma etoposide levels higher and longer than that of 160 nm etoposide-loaded PLGA nanoparticles [36] . It is generally recognized that particle sizes less than 150 nm are favored for tumor penetration [37] . Conventional nanoparticle development has sought to produce smaller, rather than larger, particle sizes, in the range of 10-100 nm. Nonetheless, the biological implications of the nanoparticulate size remains poorly defined. PTX-RUB nanoparticles were shown to enter cancer cell cultures Stability of RUB in physiological solutions and its response to dilution by a factor of 1.3, 2, 4, and 10 over 24 h following sample preparation at 37°C. Each data point represents the mean of three replicates SD. RUB, rubusoside. with similar efficacies as PTX-DMSO [2] , possibly due to their small size (Table 5 ). Whether the smaller particle size alone will translate to better pharmacokinetic profiles and efficacy remains to be elucidated.
Solubility and stability are two important factors for adequate drug exposure. Our stability profiles demonstrated that at 2.5 h 82-99% of the PTX-RUB nanoparticles remained solubilized in gastric fluid, whereas 79-96% remained solubilized in intestinal fluid, depending on the RUB concentration (from 1 to 10% w/ v). In oral medications, major intestinal absorption takes place within the first 2 h after consumption. During these 2 h, PTX is released from the PTX-RUB nanoparticles at various rates depending on the properties of the physiologic solutions. Lesser release was seen in the acidic gastric fluid than in the neutral intestinal fluid. Although PBS and intestinal fluid have similar pH values, the release of PTX from the PTX-RUB nanoparticles in the intestinal fluid was approximately half of that seen in PBS at 24 h. Although the reason is not clear, the salt in the PBS solution may have triggered a release of PTX from the nanoparticles. The RUB concentrations remained constant over the same period, indicating that RUB nanoparticles maintained their integrity under these conditions. How RUB molecules interact among themselves, and whether there were subtle changes in configuration remains to be demonstrated.
Ultimately, plasma drug levels have to reach a therapeutic range to be efficacious. Our cell viability assay demonstrated that PTX was detrimental to half of the dividing cancerous cells, of all three cells lines, at a level ranging from 4 to 20 nmol/l (Table 4) . Therefore, we suspect that plasma PTX levels may need to reach these levels to exert a therapeutic effect. A plasma PTX concentration starting at 5 nmol/l would also be effective in preventing angiogenesis (Fig. 11) . Further testing will be required to determine whether these in-vitro results translate to in-vivo efficacy. The PTX-RUB nanoparticles reported in this study will facilitate future invivo toxicology, pharmacokinetic, and efficacy studies.
In addition to addressing the PTX solubility issue, RUB appears to be capable of overcoming some cell permeability barriers. P-gp is one of the most well-recognized efflux transporters [38] . It is present in many tissues including the intestine, brain, liver, and kidney. RUB itself is a weak P-gp inhibitor compared with being a verapamil inhibitor. At 1.6 mmol/l (1 mg/ml) RUB inhibited P-gp by 59%, whereas verapamil completely blocked P-gp at only 100 µmol/l [14] . The P-gp inhibitory effects of RUB at other doses (e.g. 3 mg RUB/ml used in the Caco-2 assay) are unknown and need to be determined in future experiments. Whether cell penetration by PTX-RUB is by P-gp inhibition alone or some other mechanism such as nanoparticulation or smaller particle size is hard to define. Regardless, our PTX-RUB Cell viability of Caco-2 cells influenced by RUB. Each data point represents the mean of two independent experiments with three wells in each experiment SE. RUB, rubusoside. Cell viability influenced by PTX-RUB. The horizontal line indicates 50% cell viability. Data points represent the mean obtained from two independent experiments SE. PTX, paclitaxel; RUB, rubusoside. nanoparticles facilitated the passage of PTX across the Caco-2 cell monolayer and predict 60% intestinal absorption [39] , whereas PTX in the Taxol formulation was not permeable, in agreement with other findings [9, 10, 30] . Apparently, solubility was not the issue affecting permeability, as PTX remained soluble in both systems (Taxol or PTX-RUB). In clinical trials, converting Taxol to an oral medication was attempted in cancer patients, and a P-gp inhibitor, such as cyclosporine or verapamil, was required to improve PTX bioavailability [9, 40] . Long-term use of these inhibitors, which are immunosuppressive and calcium channel blockers, may present safety concerns. The oral PTX formulation (Paxoral) developed by IVAX Research needs cyclosporine coadministration to increase bioavailability [41] and thus faces the same dilemma. Loading PTX in lipid nanoparticles and subsequent solubilization using Solutol HS15 increased oral bioavailability three-fold over that of Taxol; however, marked interanimal variability existed [9] . In addition to the low absorption, Cremophor EL in the Taxol formulation causes hypersensitivity reactions [8, 42, 43] . Although Cremophor may not be intestinally absorbed, thus avoiding possible systemic allergic reactions, it can cause gastrointestinal toxicity [40] .
Compared with the existing nanoparticle formulations, the self-associating solubilizer and permeation-enhancing food compound, RUB, appears to hold greater promise. Although existing nanoparticle formulations appear to be conceptually sound, succeeding in both efficient delivery and safety may require major advancements in nanotechnology to adequately address their limitations. These include the insolubility of the nanoparticles, which often require an effective solubilizing ingredient for 'coating' [44] , their complexity (e.g. multiple layers) and concomitant stability, the manufacturing cost, and the potential toxicity of synthetic ingredients. The PTX-RUB nanoparticles were bioavailable to the cancer cells. In our previous study, cellular uptake of PTX in the PTX-RUB nanoparticles was found [2] . A side-by-side comparison of the cytotoxicity of PTX prepared in absolute DMSO with that prepared in an RUB water solution showed precisely that the cytotoxic and antiangiogenic properties of the drug compound were fully maintained, regardless of the solubilizing systems.
In summary, this study demonstrated that PTX can be solubilized by a natural compound, RUB, to a level of 6.3 mg/ml, which is equivalent to that in Taxol (6 mg/ml) but without the use of Cremophor and ethanol. PTX and RUB formed soluble nanoparticles with a diameter of ∼7 nm. The PTX-RUB nanoparticles can be made into a powder, which can then be instantly and completely reconstituted in physiologic solutions. In a Caco-2 permeability assay, PTX from the PTX-RUB nanoparticles was over three times more permeable than that from Taxol. When cultured with human cancer cells, cytotoxicity of the PTX-RUB nanoparticles was fully maintained, showing no statistical differences compared with DMSO-solubilized PTX. Moreover, similar antiangiogenic activity between the PTX-RUB nanoparticles and DMSO-solubilized PTX was observed. These promising results warrant further study of the PTX-RUB nanoparticles for the determination of oral bioavailability and antitumor efficacy. This study PTX, paclitaxel; RUB, rubusoside.
